Advanced Basal Cell Carcinoma: When a Common Skin Cancer Becomes Complex

Basal cell carcinoma (BCC) is the most common human cancer—usually slow-growing, locally destructive, and highly curable with early surgery. But a subset progresses to advanced BCC: locally invasive, recurrent, or metastatic disease that demands multidisciplinary management. Understanding these variants is critical for timely referral and optimal outcomes.

Three Forms of Advanced BCC

1. Locally Advanced BCC (laBCC)

Tumors that have grown deeply into surrounding structures—muscle, bone, cartilage, nerves, or orbit—making standard surgery impractical or morbid. Features include:

• Large size (>2 cm on trunk/extremities, >1 cm on face)
• Irregular, infiltrative borders
• Ulceration, fixation to deeper tissues
• Perineural invasion (PNI)—high-risk feature
• Location: "H-zone" of face (central face, periorbital, periauricular, nasolabial)

laBCC represents ~0.5–1% of all BCCs but causes disproportionate morbidity.

2. Metastatic BCC (mBCC)

Exceedingly rare (~0.0028–0.55% of BCCs). Spreads via lymphatics or hematogenously to lymph nodes, lungs, bones, skin, liver. Strongly associated with immunosuppression, prior radiation, large/neglected primary tumors, and aggressive histologic subtypes (infiltrative, morpheaform, basosquamous). Median survival historically 8–14 months, but hedgehog pathway inhibitors (HPIs) and immunotherapy are changing this.

3. Recurrent BCC

Tumor reappearance after prior treatment (surgery, radiation, topical). Recurrence rates: 1–5% for Mohs surgery, 5–15% for standard excision, higher for destructive modalities. Recurrent tumors often have aggressive subclinical extension, making re-treatment more complex. Each recurrence increases difficulty and morbidity.

Why Early Recognition Matters

Advanced BCC doesn't appear overnight. It evolves from neglected, recurrent, or high-risk primaries. Red flags for progression:

• Lesion growing despite treatment
• New symptoms: pain, numbness, paresthesia (suggests PNI)
• Fixation to underlying structures
• Rapid expansion over weeks
• Immunosuppressed patient with multiple/aggressive BCCs

Modern Management

Hedgehog Pathway Inhibitors (HPIs)

Vismodegib and sonidegib (oral SMO inhibitors) are FDA-approved for laBCC and mBCC. Objective response rates: 30–60% (laBCC), ~20% (mBCC). Toxicities: muscle spasms, dysgeusia, alopecia, weight loss, fatigue—leading to discontinuation in 20–30%. Drug holidays and lower dosing can improve tolerability.

Immunotherapy

Cemiplimab (anti-PD-1) approved for laBCC/mBCC post-HPI or intolerant. Response rates ~30%, with durable complete responses in some. Better tolerated than HPIs for many.

Multimodal Approach

Complex cases benefit from tumor board review: Mohs surgery ± reconstruction, radiation (adjuvant/definitive), HPIs, immunotherapy, clinical trials. Neoadjuvant HPIs can downstage tumors for less morbid surgery.

Prevention and Early Action

• Annual skin exams; monthly self-exams.
• Prompt biopsy of any non-healing, growing, or changing lesion.
• Mohs surgery for high-risk primaries (facial, recurrent, aggressive histology).
• Sun protection lifelong—UV drives both initiation and progression.

Advanced BCC is uncommon but consequential. Any lesion that behaves aggressively—grows fast, recurs, causes neurologic symptoms—deserves urgent specialist evaluation. Today's therapies offer real hope where few options existed a decade ago.